5AM Ventures is focused on building the next-generation of life science companies. 5AM's investment professionals employ a time-tested, hands-on approach to company building and are often directly involved in setting company strategy, management recruiting, business development and fundraising. With over $1.5B total under management, 5AM is currently funding Seed and Series A investments out of their 6th Fund, which closed at $350M at the end of 2018.
Areas of interest include:
- Early Stage Therapeutics: Modality and indication agonistic. 5AM focuses on novel biology identifying new targets and pathways to drug for therapeutic effect; and novel modality platforms. 5AM gravitates toward pre-clinical opportunities where there are compelling mechanistic, cell, and/or animal model proof of concept data, and invest through pre-clinical and into clinical proof of concept.
- Drug Delivery Platforms: Novel ways to deliver drugs that are already on the market, to enhance their safety and/or efficacy profiles, improve health economics, and ultimately improve patient outcomes. These products generally go through the FDA 505(b)(2) regulatory pathway.
- Research Tools and Technologies: Technology platforms (instruments and consumables, reagents) that enable novel scientific insights in the research and drug development spaces. Interest areas include genomics and proteomics, synthetic biology, and single cell biology.